• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Crizotinib - Articles and news items

Crizotinib lung cancer price drop

NICE recommends Pfizer’s lung cancer drug after price drop

Industry news / 18 August 2016 / The National Institute for Health and Care Excellence (NICE)

When initially reviewed, the committee concluded that the drug was too expensive compared to the current standard of care. Pfizer submitted further evidence, including a new patient access scheme that provided the drug at a lower price alongside revised analyses, which the committee then concluded could now be considered value for money on the NHS…


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +